Drug Trial Radar · NCT06964009
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Elizabeth Stover, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense; Dialectic Therapeutics, Inc; American Society of Clinical Oncology
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Conditions
- Ovarian Cancer
- Ovarian Carcinoma
- Recurrent Ovary Cancer
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Endometrial Cancer
- Endometrial Adenocarcinoma
- Recurrent Endometrial Carcinoma
Interventions
DT2216Drug
A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.
PaclitaxelDrug
An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DT2216 Maximum Tolerated Dose (MTD)Time frame: Assessed on Day 1, 4, 8, 11, 15, 18, 22 and 25 on cycle 1 and up to start of cycle 2; cycle 1 duration=28 days plus 14 days maximum until start of cycle 2, for a maximum time frame of 42 days.
- Number of Participants Experiencing a Dose-Limiting Toxicity (DLT)Time frame: Assessed on Day 1, 4, 8, 11, 15, 18, 22 and 25 on cycle 1 and up to start of cycle 2; cycle 1 duration=28 days plus 14 days maximum until start of cycle 2, for a maximum time frame of 42 days.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.